Eligibility and Response to Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Therapy: How Useful Are Cardiac Biomarkers?
作者信息
Echouffo-Tcheugui Justin B, Selvin Elizabeth
机构信息
Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins School of Medicine, Baltimore, Maryland, USA; Welch Prevention Center for Prevention, Epidemiology and Clinical Research; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Welch Prevention Center for Prevention, Epidemiology and Clinical Research; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
出版信息
J Am Coll Cardiol. 2022 Feb 8;79(5):445-447. doi: 10.1016/j.jacc.2021.11.028.
Abstract
摘要
相似文献
1
Eligibility and Response to Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Therapy: How Useful Are Cardiac Biomarkers?钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂治疗的 eligibility 及反应：心脏生物标志物有多大作用？ （注：“eligibility”在这里结合语境推测可能是指“适用性”之类的意思，但按要求未添加解释）
J Am Coll Cardiol. 2022 Feb 8;79(5):445-447. doi: 10.1016/j.jacc.2021.11.028.
2
Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.基于模型的健康和糖尿病患者近端钠重吸收的 SGLT2 评估及坎格列净抑制作用
J Clin Pharmacol. 2018 Mar;58(3):377-385. doi: 10.1002/jcph.1030. Epub 2017 Nov 16.
3
Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.钠/葡萄糖协同转运蛋白（SGLT）2抑制剂卡格列净与SGLT1和SGLT2的相互作用。
J Pharmacol Exp Ther. 2016 Jul;358(1):94-102. doi: 10.1124/jpet.116.232025. Epub 2016 Apr 27.
4
Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.钠-葡萄糖共转运蛋白 2 抑制剂卡格列净通过抑制葡萄糖摄取来抑制肝癌细胞生长和血管生成活性。
Int J Cancer. 2018 Apr 15;142(8):1712-1722. doi: 10.1002/ijc.31193. Epub 2017 Dec 12.
5
High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection.高基底外侧葡萄糖通过葡萄糖转运蛋白 2 检测增加肾脏近端小管钠-葡萄糖协同转运蛋白 2 并减少 Sirtuin-1。
Sci Rep. 2018 May 1;8(1):6791. doi: 10.1038/s41598-018-25054-y.
6
Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.SGLT2抑制剂的最新进展——美国糖尿病协会发布的新数据
Crit Pathw Cardiol. 2017 Sep;16(3):93-95. doi: 10.1097/HPC.0000000000000125.
7
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.钠-葡萄糖协同转运蛋白2抑制剂对血压的影响。
Vasc Health Risk Manag. 2016 Oct 27;12:393-405. doi: 10.2147/VHRM.S111991. eCollection 2016.
8
Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice.卡格列净，一种钠-葡萄糖协同转运蛋白 2 抑制剂，可减轻肥胖诱导的小鼠迷走神经节、下丘脑和骨骼肌的炎症。
Eur J Pharmacol. 2017 Jan 5;794:37-44. doi: 10.1016/j.ejphar.2016.11.028. Epub 2016 Nov 19.
9
Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol.钠-葡萄糖协同转运蛋白2抑制剂卡格列净（Invokana）对改变血浆1,5-脱水葡萄糖醇作用的模型分析
Clin Chim Acta. 2016 Jan 15;452:138-41. doi: 10.1016/j.cca.2015.11.010. Epub 2015 Nov 10.
10
Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy.探索钠-葡萄糖共转运蛋白作为癌症治疗新靶点的作用。
J Pharm Pharm Sci. 2022;25:253-265. doi: 10.18433/jpps32879.
本文引用的文献
1
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.应激性心脏生物标志物、心血管和肾脏结局以及对卡格列净的反应。
J Am Coll Cardiol. 2022 Feb 8;79(5):432-444. doi: 10.1016/j.jacc.2021.11.027.
2
Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.心脏病与中风统计-2021 更新：美国心脏协会报告。
Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950. Epub 2021 Jan 27.
3
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58.DECLARE-TIMI 58 研究中基线心脏生物标志物与钠-葡萄糖共转运蛋白 2 抑制剂治疗有或无心力衰竭心血管死亡或住院的关系。
Eur J Heart Fail. 2021 Jun;23(6):1026-1036. doi: 10.1002/ejhf.2073. Epub 2020 Dec 29.
4
Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.卡格列净对氨基末端 pro-B 型利钠肽的影响：对降低心血管风险的意义。
J Am Coll Cardiol. 2020 Nov 3;76(18):2076-2085. doi: 10.1016/j.jacc.2020.09.004.
5
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.SGLT2 抑制剂与 2 型糖尿病患者心血管和肾脏结局的关联：一项荟萃分析。
JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511.
6
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.2020年2型糖尿病患者降低心血管风险新型疗法专家共识决策路径：美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5.
7
Omics and Cardiometabolic Disease Risk Prediction.组学与心血管疾病风险预测。
Annu Rev Med. 2020 Jan 27;71:163-175. doi: 10.1146/annurev-med-042418-010924.
8
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.SGLT2 抑制剂用于 2 型糖尿病的心血管和肾脏结局的一级和二级预防：心血管结局试验的系统评价和荟萃分析。
Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.
9
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病患者的心血管结局：一项荟萃分析。
Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. doi: 10.1016/S2213-8587(17)30412-6. Epub 2017 Dec 6.
10
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
Zotero 插件